$100 for a Covid-19 vac­cine? That's what Mod­er­na says may be com­ing

As Mod­er­na piv­ots away from Covid-19 to oth­er vac­cines, the mR­NA-fo­cused biotech is still plot­ting how it could hit $13 bil­lion in an­nu­al US Covid-19 vac­cine sales, with $100 shots and 50% of all adults get­ting a boost­er.

But the Boston-based com­pa­ny’s lofty ex­pec­ta­tions, re­vealed in a slide show yes­ter­day as part of its R&D day, in­clud­ed an es­ti­mate that the world­wide pan­dem­ic Covid-19 vac­cines mar­ket is worth more than $100 bil­lion glob­al­ly, as in high-in­come coun­tries, the el­i­gi­ble high-risk pop­u­la­tion (el­der­ly and those with high risk) is about 340 mil­lion peo­ple.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER